GT Apeiron Therapeutics is a Shanghai-based biotech company that uses artificial intelligence and other emerging technologies to accelerate drug discovery. The company works with Exscientia’s automated AI drug discovery platform as part of a collaboration to speed target selection, hit identification and lead optimization. Apeiron’s initial therapeutic focus is oncology and it intends to develop investigational medicines through pre-clinical studies and clinical trials. Launched in 2019 by a team with extensive drug discovery expertise, the company combines AI-driven workflows with traditional discovery approaches. Financially, the company announced a $27M funding raise to support its discovery and development activities.

Total raised

$27M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2019